Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
PURAZINE TABLETS SCHEDULING STATUS: S2 PROPRIETARY NAME: (and dosage form) PURAZINE TABLETS COMPOSITION: Each tablet contains 25 mg Cinnarizine . PHARMACOLOGICAL CLASSIFICATION: A 5.7 - Antihistamines, anti-emetics and anti-vertigo preparations. PHARMACOLOGICAL ACTION: Cinnarizine has the properties of an antihistamine. Its effect lasts for about 4 hours. INDICATIONS: Nausea and vertigo due to Meniéres disease and symptoms of other labyrinthine disturbances and for the prevention and treatment of motion sickness. CONTRA-INDICATIONS: Cinnarizine should not be administered to patients sensitive to the medicine and to pregnant women, or those who may become so, as this medicine has been demonstrated to have teratogenic effects in laboratory animals. Cinnarizine is contra-indicated during acute attacks of asthma. WARNING: THE USE OF THIS MEDICINE LEADS TO DROWSINESS WHICH IS AGGRAVATED BY THE SIMULTANEOUS INTAKE OF ALCOHOL OR OTHER CENTRAL NERVOUS SYSTEM DEPRESSANT AGENTS. DOSAGE AND DIRECTIONS FOR USE: Adults: One tablet 3 times per day. This may be increased to 9 tablets daily if necessary. Treatment should be started in the early stages of the disease and should continue uninterrupted for several weeks or months or longer periods. For the prophylaxis of motion sickness, 1 tablet should be given 1 hour before departure and this dosage may be repeated every 6 to 8 hours. Children: Children aged 5 to 7 years may be given 15 to 20 mg daily in divided doses and older children up to 30 mg daily according to age. SIDE-EFFECTS AND SPECIAL PRECAUTIONS: The most common effect is sedation, varying from slight drowsiness to deep sleep and including lassitude, dizziness and inco-ordination. Other side effects include gastro-intestinal disturbances such as nausea, vomiting, diarrhoea or consti Read the complete document